Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJose TinajeroHMHuiyan MaSPSunmin Park

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals RAS mutations correlate with worse outcomes post-transplant, suggesting improved clearance may enhance survival.

Key Points

  • To assess the impact of RAS pathway mutations on outcomes following allogeneic transplant in AML patients.
  • Retrospective analysis of adults with RAS mutations and AML receiving alloHCT.
  • Evaluation of overall survival, leukemia free survival, graft versus host disease incidence, and relapse rates.
  • Next generation sequencing conducted for mutation detection.
  • 2- and 5-year overall survival were 56.7% and 47.7%; leukemia free survival was 53.5% and 48.4%.
  • Persistence of RAS mutations pre-transplant correlated with decreased overall survival and increased relapse rates.
  • Graft versus host disease incidence was recorded but not specified in details.

Cite This Study

Tinajero et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5e9https://doi.org/10.1182/blood-2025-4305
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP2025
  2. 2Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT2025
  3. 3Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study2025
  4. 4Disease biology rather than donor type determines transplant outcomes in KMT2A-rearranged AML2026
  5. 5Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.2026